NEW YORK (GenomeWeb News) – With the help of the National Cancer Institute, CvergenX is developing a radiosensitivity test for use in determining how patients respond to radiation therapy, the company said late Tuesday.

NCI has chosen CvergenX's technology called InterveneXRT for further development and validation in a commercial collaboration in order to advance the assay for use in clinical trials and potentially approval by the US Food and Drug Administration. CvergenX is developing the technology in conjunction with NCI's Clinical Assay Development Program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.